A Complete Guide to Neupogen: Uses, Dosage, Side Effects, and Precautionary Measures

Published on by Dr. Christine Leduc, PharmD

Neupogen (filgrastim) is an injectable medicine used to treat or prevent neutropenia (low neutrophil levels) in certain patients, including people receiving cancer treatments like chemotherapy. Neutropenia is a condition in which your body has a low white blood cell count, particularly neutrophils, which fight bacterial and fungal infections. Neupogen helps reduce the risk of infections by stimulating neutrophil production in cancer patients. 

Get Financial Assistance

(877) 778-0318

Neupogen (filgrastim) is manufactured by Amgen and was approved by the FDA in 1991. Currently, five biosimilars of this drug are available in the market, including Filkri, Nivestym, Nypozi, Releuko, and Zarxio. 

If you’ve received a Neupogen prescription from your oncologist, then this article is for you. Read on to learn more about Neupogen, how it works, its dosage, the side effects you can expect, and the precautions you should take. 

Indications (Uses)

The FDA has approved Neupogen (filgrastim) for several uses, including:

  • To reduce the risk of serious infections due to a low white blood cell count in people with certain types of cancer (non-myeloid) who received chemotherapy.
  • To help neutrophils recover faster after intensive chemotherapy in patients with acute myeloid leukemia (AML).
  • To help the cancer patient’s neutrophil count recover more quickly after bone marrow or stem-cell transplantation.
  • To move blood-forming stem cells from the bone marrow into the bloodstream before patients undergo stem-cell collection therapy.
  • When a person has persistently or repeatedly low neutrophils, such as congenital neutropenia, cyclic neutropenia, and idiopathic neutropenia.
  • To stimulate bone marrow recovery after severe radiation exposure, which has severely damaged blood-cell production.
  • To increase survival in patients exposed to bone marrow-suppressing radiation. 

Neupogen: Mode of Action (MOA)

When cancer patients receive high-dose chemotherapy treatment, it also damages the bone marrow cells, which results in a significant reduction in the number of white blood cells, including neutrophils, in the blood circulation. 

Since the cancer patient’s bone marrow needs time to produce new infection-fighting white blood cells, these patients are at high risk of serious infection due to neutropenia (low neutrophil counts). 

Neupogen (filgrastim) speeds up neutrophil production. Neupogen is a granulocyte colony-stimulating factor (G-CSF), which the body also produces naturally. G-CSF normally acts on the bone marrow and boosts the production of neutrophils. 

Neupogen works like the body’s natural G-CSF, helping white blood cells mature faster into neutrophils and enter the bloodstream to fight bacteria and reduce infection risk. 

Neupogen: Drug Form

Neupogen is available as a liquid solution in both single-dose vials and single-dose prefilled syringes in the following strengths:

  • Single-dose vials: 300 mcg/ml and 480 mcg/1.6 ml
  • Prefilled syringe: 300 mcg/0.5 ml and 480 mcg/0.8 ml

Your doctor determines the dosage and duration of Neupogen based on your condition, treatment, and blood-cell counts. Recommended dosages vary depending on the condition being treated:

1. Dosage for Cancer Patients Receiving Chemotherapy

The recommended initial dosage for patients with AML or non-myeloid cancers receiving chemotherapy is 5 mcg/kg/day, which can be administered as a single daily subcutaneous injection, by short intravenous infusion (15 to 30 minutes), or by continuous intravenous infusion.

2. Dosage for Cancer Patients Undergoing Bone Marrow Transplantation

The recommended dosage of Neupogen following bone marrow transplantation (BMT) is 10 mcg/kg/day, which is given as an intravenous infusion no longer than 24 hours. The first dose should be administered at least 24 hours after chemotherapy and at least 24 hours after bone marrow infusion. 

3. Dosage for Patients Undergoing Bone Marrow Collection Therapy

For collecting a patient’s own stem cells from the blood, Neupogen is given as a subcutaneous injection under the skin at a dosage of 10 mcg/kg/day. The first dose is given at least 4 days before the first leukapheresis procedure and continues until the last leukapheresis.

4. Dosage for Patients with Severe Chronic Neutropenia

The initial dosage of Neupogen in patients with congenital neutropenia is 6 mcg/kg, given as a subcutaneous injection twice a day. In patients with idiopathic or cyclic neutropenia, the dosage is 5 mcg/kg as a single daily subcutaneous injection.

5. Dosage for Patients Exposed to Bone Marrow-Suppressing Radiation

For patients who are exposed to myelosuppressive doses of radiation, a dose of 10 mcg/kg is given as a single daily subcutaneous injection. The Neupogen should be administered as soon as possible after suspected or confirmed exposure to radiation doses greater than 2 gray (Gy).

Do You Qualify for $0 Copay?

Find Out Now

How It Is Administered

Neupogen may be given as a subcutaneous injection under the skin. Your healthcare provider will show you how and where the injection should be given if you are administering Neupogen at home.

In some cases, Neupogen is also given as an intravenous injection, where a healthcare provider directly administers the drug solution into your vein. 

Side Effects

Woman with a fever lying on couch, suffering a side effect from taking Neupogen

The most common side effects of Neupogen vary depending on the condition being treated and how the medication is used. For instance:

  • Patients with non-myeloid cancers receiving chemotherapy may experience fever, pain, rash, cough, and shortness of breath.
  • Patients with Acute myeloid leukemia receiving chemotherapy may have pain, nosebleeds, and rash.
  • Non-myeloid cancer patients receiving chemotherapy followed by bone marrow transplant may have rash.
  • People having their own blood cells collected may have bone pain, fever, and headache.
  • Patients with severe chronic neutropenia may have pain, decreased red blood cells, nosebleeds, diarrhea, reduced sensation, and hair loss. 

Serious Side Effects

Patients taking Neupogen could also experience some adverse effects. Some of the reported serious effects of this medicine include:

  • Spleen rupture
  • Acute respiratory distress syndrome (a serious lung problem)
  • Serious allergic reactions
  • Sickle cell crises in people with sickle cell disorder
  • Kidney injury
  • Capillary leak syndrome (CLS)
  • Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
  • Decreased platelet count (thrombocytopenia)
  • Increased white blood cell count (leukocytosis)
  • Inflammation of your blood vessels (cutaneous vasculitis)
  • Inflammation of arteries (arteritis)

Contact your healthcare provider right away if you develop signs or symptoms of a serious side effect while taking Neupogen. Your healthcare provider will determine whether treatment should be stopped or adjusted.

Precautionary Measures

Before you receive Neupogen, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a sickle cell disorder. 
  • Have kidney problems. 
  • Are receiving radiation therapy. 
  • Are allergic to latex because the needle cap on the Neupogen prefilled syringe contains dry natural rubber (derived from latex). Do not use Neupogen with the prefilled syringe if you have latex allergies. 
  • Are pregnant or plan to become pregnant. It is not known if Neupogen will harm your unborn baby. 
  • Are breastfeeding or plan to breastfeed. It is not known if Neupogen passes into your breast milk. 
  • Are taking any other medicines, such as prescription and over-the-counter medicines, vitamins, and herbal supplements

Speak to a Specialist

About Copay Assistance
(877) 778-0318

Cost

Neupogen can be expensive for people paying without insurance. The cash price can vary depending on the dose, pharmacy, location, and insurance coverage. For example, a 300 mcg/0.5 ml injection may cost around $334 per dose, while a 480 mcg/0.8 ml injection may cost around $527. Check with your pharmacy or insurance provider for current pricing and coverage information.

If the cost of Neupogen is a concern, your healthcare provider may consider an available filgrastim biosimilar when appropriate. Insurance coverage and out-of-pocket costs can vary by product. You can also contact us if you are interested in financial assistance or copay assistance for Neupogen.

Epogen for Anemia: Uses, Dosage, Side Effects, and Safety Measures

Published on by Dr. Christine Leduc, PharmD

Epoetin alfa is an FDA-approved medicine to treat anemia associated with chemotherapy, chronic kidney disease (CKD), or zidovudine treatment in patients with HIV. While Epogen and Procrit share the same active ingredient (epoetin alfa), they are marketed for different uses: Epogen is primarily indicated for patients on dialysis, whereas Procrit is marketed for non-dialysis uses and oncology adjunctive care. Epogen was initially marketed by Amgen in 1989, while Procrit is distributed by Johnson & Johnson.

Get Financial Assistance

(877) 778-0318

You can get Epogen as an injection under the skin or directly into your dialysis line. The dosage of Epogen may vary depending on your condition. Some common side effects of this drug include high blood pressure, fever, and muscle or joint pain. 

Read on to learn how Epogen works, when it is used, its dosage, and safety measures. 

FDA-Approved Uses

Epogen is approved by the FDA to treat anemia in patients if it is caused by:

  • Chronic kidney disease (a patient who may or may not be on dialysis)
  • Cancer chemotherapy that will be used for at least 2 months after starting Epogen
  • An antiviral drug called zidovudine (AZT) used to treat HIV

Epogen may also be used to reduce the need for blood transfusion during certain types of surgeries, where a lot of blood loss is expected.

Boxed Warnings

Epogen may cause serious side effects that can lead to death. In some clinical studies involving patients with certain cancers, erythropoiesis-stimulating agents (ESAs) shortened overall survival and/or increased the risk of tumor progression or recurrence. 

Moreover, people taking Epogen may experience serious cardiovascular and thromboembolic events, including heart attack, stroke, and blood clots. In patients with chronic kidney disease, targeting hemoglobin levels above 11 g/dl with ESAs has been associated with an increased risk of death and serious cardiovascular reactions. 

Therefore, it is highly recommended to discuss the risks and benefits of Epogen with your healthcare provider. 

Mechanism of Action

Epogen is the man-made version of human erythropoietin (EPO). EPO is a protein that is naturally produced by your kidneys that stimulates the bone marrow to produce more red blood cells (RBCs). When you have chronic kidney disease or certain other medical conditions, your body may not produce enough red blood cells, which can lead to anemia.

Epoetin alfa, the active substance of Epogen, mimics the function of natural erythropoietin (EPO) protein and causes the bone marrow to produce more red blood cells. This helps treat anemia and improves oxygen delivery in the body. 

Epogen: Drug Form

Epogen is available as a sterile liquid solution in single-dose and multiple-dose vials. The single-dose vials are available in strengths of 2,000, 3,000, 4,000, and 10,000 units/ml, while the multiple-dose vials are available as 20,000 units/2 ml (10,000 units/ml) and 20,000 units/ml.

Note: Units/ml tells you how much epoetin alfa is present in 1 ml of solution. For example, 2,000 units/ml means 1 ml of Epogen contains 2,000 units of epoetin alfa. 

Dosage and Administration

Epogen is administered either under the skin (subcutaneously) or into a vein (intravenously). The Epogen dosage is adjusted based on the patient’s condition, hemoglobin level, response to treatment, and other clinical factors. Below are general FDA-labeled starting regimens for Epogen based on the condition being treated:

1. Dosage for Chronic Kidney Disease (CKD) 

The initial recommended dose of Epogen is 50–100 units/kg, given three times per week, either intravenously or subcutaneously. For patients with CKD on hemodialysis, the intravenous route is recommended. 

2. Dosage for Zidovudine-Treated Patients with HIV Infection

The recommended starting dose of Epogen in patients treated with zidovudine is 100 units/kg, which is given as an intravenous or subcutaneous injection three times per week. 

The starting dose of Epogen for adults is 150 units/kg subcutaneously three times per week or 40,000 units once a week by subcutaneous injection until completion of a chemotherapy course. 

For pediatric patients (5 to 18 years), a dose of 600 units/kg of Epogen is given intravenously once a week until completion of a chemotherapy course.

4. Dosage for Patients Undergoing Surgery

If a patient is undergoing a surgical procedure, they may receive a dose of 300 units/kg daily for 10 days before surgery, on the day of surgery, and for 4 days afterward. 

Alternatively, a dose of 600 units/kg once weekly for 3 weeks before surgery and on the day of surgery may be given, depending on the patient’s condition.

Do You Qualify for $0 Copay?

Find Out Now

Who Should Not Take Epogen? 

You should not take Epogen if you: 

  • Have uncontrolled high blood pressure.
  • Have developed pure red cell aplasia (PRCA) after treatment with Epogen or other erythropoietin protein medicines.
  • Have had a serious allergic reaction to Epogen.

Side Effects

Epogen may cause some common side effects, as well as potentially serious side effects depending on the condition being treated. 

Common Side Effects

Woman suffering from nausea as a side effect of taking Epogen

Common side effects vary depending on the condition being treated. Reported adverse reactions include: 

  • Joint, muscle, or bone pain 
  • Fever, chills, cough 
  • Rash
  • Nausea, vomiting
  • Soreness of mouth
  • Itching
  • Headache
  • Dizziness
  • Blood vessel blockage
  • Respiratory infection
  • High blood sugar 
  • Low white blood cells
  • Weight decrease 
  • Low potassium levels in the blood 
  • Trouble sleeping (insomnia)
  • Depressed mood
  • Difficulty swallowing 
  • Muscle spasm 
  • Redness and pain at the Epogen injection site

Serious Side Effects 

  • Heart attack 
  • Stroke 
  • Heart failure 
  • Blood clots (thrombosis) 
  • Severe hypertension 
  • Seizures 
  • Serious allergic reactions 
  • Severe skin reactions 
  • Pure red cell aplasia (PRCA), a rare condition in which the bone marrow stops producing red blood cells

Get Copay Assistance Now

(877) 778-0318

Safety Measures

To ensure Epogen is safe for you, tell your healthcare provider if you:

  • Have heart disease. 
  • Have high blood pressure. 
  • Have had a seizure (convulsion) or stroke. 
  • Receive dialysis treatment. 
  • Are pregnant or plan to become pregnant. It is not known if Epogen may harm your unborn baby. Talk to your healthcare provider about possible pregnancy and birth control choices that are right for you. 
  • Are breastfeeding or plan to breastfeed. It is not known if Epogen passes into breast milk.
  • Are taking any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Epogen: Estimated Cost

Epogen can be expensive, as the price varies by strength and quantity. Since Epogen is a branded drug, patients who find it difficult to afford may consider Retacrit (epoetin alfa-epbx) as an alternative. 

Retacrit is an FDA-approved biosimilar of Epogen and was approved on May 15, 2018. Biosimilars are highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, purity, or potency, and may be available at a lower cost. The table below compares the costs of Epogen and Retacrit:

StrengthEpogenRetacrit (biosimilar)
2,000 Units/mL, 10 ml$331.81$234.12
3,000 Units/mL, 10 ml$493.76$347.22
4,000 Units/mL, 10 ml$655.71$460.32
10,000 Units/mL, 10 ml$1,627.43$1,138.97
10,000 Units/mL, 20 ml$3,246.97$2,270.04
20,000 Units/mL, 10 ml$3,246.97$2,270.04
40,000 Units/mL, 4 mlN/A$1,817.61

Talk to your healthcare provider before switching to a biosimilar such as Retacrit. If cost is a concern, contact us to explore financial or copay assistance for Epogen.

Ixifi (Infliximab-qbtx): Uses, Dosage, Side Effects, and Cost

Published on by Dr. Robert Hakim, PharmD

Ixifi (infliximab-qbtx) is an FDA-approved biologic prescription medication made using living cells. It is used to treat certain inflammatory and autoimmune conditions like rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. 

Get Copay Assistance Now

(877) 778-0318

The FDA first approved Ixifi on December 13, 2017. It was approved as a biosimilar to Remicade (infliximab), meaning it is highly similar to the reference product, with no clinically meaningful differences in safety, purity, or potency. Other infliximab biosimilars include Inflectra and Renflexis.

The active ingredient in Ixifi is infliximab. It works by blocking a protein called TNF-alpha, which causes inflammation in your body. Ixifi comes as a 100 mg powder in a single-dose vial that is mixed with liquid before it is given as an intravenous (IV) infusion.

In this article, we’ll cover Ixifi uses, dosage, side effects, precautions, cost, and more. 

What Is Ixifi Used For?

Ixifi is an FDA-approved medication to treat the following conditions [2][3]:

Crohn’s Disease: In adult patients with moderate to severe active Crohn’s disease, Ixifi can:

  • Reduce the signs and symptoms of the disease
  • Induce and maintain clinical remission when conventional treatments have not worked well
  • Reduce the number of draining enterocutaneous and rectovaginal fistulas
  • Help maintain fistula closure in adults with fistulizing Crohn’s disease

Pediatric Crohn’s Disease: Healthcare providers use Ixifi in children 6 years of age and older with moderate to severe active Crohn’s disease. It can reduce signs and symptoms of the disease and induce and maintain clinical remission.

Ulcerative Colitis: Ixifi is used in adults and children 6 years and older with moderate to severe active ulcerative colitis when conventional treatments have not worked well. Ixifi can reduce your symptoms, induce and maintain remission, promote mucosal healing, and help eliminate the need for corticosteroids in adults.

Rheumatoid Arthritis: If you have moderate to severe rheumatoid arthritis, you can use Ixifi in combination with methotrexate. It can help reduce the symptoms, slow the progression of structural joint damage, and improve physical function.

Ankylosing Spondylitis: Ixifi can reduce the symptoms in adults with ankylosing spondylitis.

Psoriatic Arthritis: Ixifi is used in adults with psoriatic arthritis. It can improve your symptoms, slow the progression of joint damage, and improve physical function.

Plaque Psoriasis: Ixifi is used in adults with chronic, severe plaque psoriasis who are candidates for treatment with systemic medications and when other systemic treatment options are medically less appropriate.

Please note that Ixifi does not cure these conditions. Instead, it blocks the activity of TNF-alpha (a protein that promotes inflammation) to control the inflammation responsible for many of the symptoms.

How Does Ixifi Work?

Your immune system normally protects the body from infections and other harmful substances. However, in autoimmune and inflammatory diseases, your immune activity can become excessive or persist for too long. TNF-alpha is an important protein that is involved in this process. It promotes inflammation and contributes to the symptoms and tissue damage associated with several inflammatory diseases.

Ixifi contains the active ingredient infliximab-qbtx. It is a monoclonal antibody that blocks TNF-alpha. By doing this, it reduces the inflammation that causes symptoms and tissue damage.

For example, in Crohn’s disease and ulcerative colitis, excessive inflammation in your digestive tract can cause abdominal pain, diarrhea, bleeding, and other symptoms. By blocking TNF-alpha, Ixifi reduces this inflammation and promotes clinical remission.

Do You Qualify for $0 Copay?

Find Out Now

Ixifi Side Effects

Here are some of the common and serious side effects of Ixifi [3]:

Common Side Effects

Woman on couch holding stomach due to pain caused by side effects of taking Ixifi
  • Respiratory infections, such as sinus infections and sore throats
  • Headache
  • Coughing
  • Stomach pain
  • Infusion-related reactions
  • Viral infections

These side effects are usually mild, but tell your doctor if they persist or get worse.

Serious Side Effects and Warnings 

Serious side effects from Ixifi are rare, but they can occur. Here are some serious side effects and warnings associated with Ixifi: 

Serious Infections: Ixifi can increase the risk of serious infections because it suppresses your immune system. These infections can include tuberculosis (TB), bacterial infections, and invasive fungal infections. Ixifi should be discontinued if you develop a serious infection or sepsis. 

Cancer: Lymphoma and other malignancies, some fatal, have been reported in children and adults treated with TNF blockers, including infliximab products. Your doctor will consider the potential risks and benefits of treatment, particularly if you have risk factors for certain cancers. 

Heart Failure: Ixifi can cause heart failure or make existing heart conditions worse. Tell your doctor if you have symptoms of heart failure, such as shortness of breath, swelling of the ankles or feet, or sudden weight gain. 

Liver Problems: In rare cases, Ixifi can cause liver problems. Severe liver injury, including cases resulting in liver transplant or death, has been reported with infliximab products. Contact your doctor if you experience symptoms such as yellowing of the skin or eyes, dark urine, severe fatigue, fever, or pain on the right side of your abdomen. 

Severe Allergic and Infusion Reactions: Ixifi can cause serious allergic or infusion reactions during or shortly after the infusion. Symptoms may include difficulty breathing, hives, chest pain, swelling, dizziness, or a significant change in blood pressure.

Please note that this is not a complete list of all possible side effects. Contact your doctor immediately if you experience any severe or unusual symptoms while receiving Ixifi.

Dosing of Ixifi

Ixifi comes as a powder that is mixed with liquid before use. You’ll receive it through an intravenous (IV) infusion. The exact dose depends on the condition being treated, your body weight, and how you respond to treatment. Your healthcare provider will determine the right dosage for you. Below are the usual recommended dosages [2][3]:

Crohn’s Disease: For adult patients, the usual initial dose is 5 mg/kg given at week 0, week 2, and week 6. After these initial doses, 5 mg/kg is given every 8 weeks. For those who initially responded to the treatment but later have an inadequate response, the doctor may increase the dose to 10 mg/kg every 8 weeks.

For children aged 6 years and older, the dosage is 5 mg/kg given at week 0, week 2, and week 6, followed by 5 mg/kg every 8 weeks.

Ulcerative Colitis: For adults and children aged 6 years and older, the recommended dose is 5 mg/kg at week 0, week 2, and week 6, followed by 5 mg/kg every 8 weeks.

Rheumatoid Arthritis: Ixifi is used in adult patients in combination with methotrexate. The recommended dosage is 3 mg/kg given at week 0, week 2, and week 6, followed by 3 mg/kg every 8 weeks. Some patients may benefit from increasing the dose to up to 10 mg/kg every 8 weeks or receiving treatment as frequently as every 4 weeks, depending on their response.

Ankylosing Spondylitis: The recommended adult dose is 5 mg/kg given at week 0, week 2, and week 6, followed by 5 mg/kg given every 6 weeks.

Psoriatic Arthritis and Plaque Psoriasis: The recommended adult dose is 5 mg/kg given at week 0, week 2, and week 6, followed by 5 mg/kg given every 8 weeks.

Speak to a Specialist

About Copay Assistance
(877) 778-0318

Before Starting Ixifi

Before you start Ixifi, tell your healthcare provider your complete medical history, including whether you [3]:

  • Have an active infection or a history of infections that keep coming back
  • Have tuberculosis or have been in close contact with someone who has TB
  • Have hepatitis B or have previously had hepatitis B
  • Have heart failure or other heart problems
  • Have a history of cancer
  • Have a blood disorder or a history of abnormal blood counts
  • Are pregnant, planning to become pregnant, or breastfeeding
  • Take methotrexate, corticosteroids, azathioprine, 6-mercaptopurine, or other medicines that suppress the immune system
  • Take any medicines, vitamins, or herbal supplements
  • Have previously had an allergic reaction to infliximab or another biologic medicine

You should avoid live vaccines while receiving Ixifi because there’s a chance it can make you sick. Children receiving treatment should have their vaccinations reviewed before starting therapy.

Ixifi Cost

Ixifi is an expensive biologic medication. The total cost can vary depending on your condition, body weight, number of vials needed, the treatment schedule, insurance coverage, and where you receive treatment.

As one example, the listed price in Ontario, Canada, is about CAD $493 per 100-mg vial [4]. Prices in the U.S. and other locations may differ. For Crohn’s disease and ulcerative colitis, the recommended dose is 5 mg/kg at weeks 0, 2, and 6, followed by a 5 mg/kg dose every 8 weeks [3]. So, an 80-kg adult would need 400 mg per infusion, requiring four vials. This would cost approximately CAD $1,972 without insurance. 

Patients concerned about treatment expenses can explore Ixifi copay assistance programs to help reduce out-of-pocket costs.

2027 Medicare Open Enrollment Guide: What You Need To Know

Published on by David Mogote

Insights from AmeriPharma Specialty’s Billing and Insurance Coverage Support Team

If you’re on a specialty medication like IVIG, TPN, oncology, or biologics, the 2027 open enrollment period is one of the most important windows of the year to review your insurance plan.

At AmeriPharma Specialty Care, our team supports thousands of patients across Medicare, Marketplace, and commercial insurance plans. Each year, we help patients avoid coverage gaps, uncover assistance opportunities, and resolve issues that could have been prevented with earlier planning.

This guide shares the top questions we hear, the most common mistakes we see, and what you need to know to protect your access to treatment in 2027.

We guide. You decide.
AmeriPharma helps you understand how your therapy is covered and where to look for financial assistance. AmeriPharma is not an insurance agent, and we do not recommend specific plans.

Key Open Enrollment Dates (for 2027 Coverage)

  • Medicare Annual Open Enrollment (AEP):
    October 15 – December 7, 2026
    Changes take effect January 1, 2027.
  • ACA Marketplace Plans:
    Marketplace enrollment is separate from Medicare. Dates and effective-date rules vary by state and marketplace; verify the current 2027 schedule at HealthCare.gov or your state marketplace. People who have Medicare generally should not purchase Marketplace coverage.
  • Employer Plans:
    Dates vary, but most are in October–December

How to Compare Plans for Specialty Therapies

1. Ask These Three Questions First

Every year, we speak to patients who chose plans based on monthly premiums — only to discover that their medication isn’t covered, or they’re locked into a pharmacy that can’t meet their needs.

Before selecting any plan, we recommend confirming these three things:

  • Is my medication on your formulary? What tier is it?
  • Do I have to use a specific specialty pharmacy? If yes, can I request an exception?
  • For Medicare Advantage plans: Does my provider work with the specified plan?

These three answers affect access, cost, and whether your prescriber and preferred specialty pharmacy can support you. Too often, patients skip this step—only to discover later that their plan won’t allow them to use their preferred pharmacy, or that starting treatment will be delayed while a new pharmacy is arranged.

2. Look at the Whole Cost — Not Just the Premium

Each year during open enrollment, we see patients choose plans with the lowest monthly premium, thinking they’re saving money — only to be surprised by higher out-of-pocket costs, pharmacy restrictions, or treatment delays once the year begins.

The reality is: A low premium doesn’t always mean a low total cost—especially if you’re on a specialty therapy.

Before selecting any plan, we recommend confirming these three things:

  • Is my medication on your formulary? What tier is it?
  • Do I have to use a specific specialty pharmacy? If yes, can I request an exception?
  • For Medicare Advantage plans: Does my provider work with the specified plan?

These three answers affect access, cost, and whether your prescriber and preferred specialty pharmacy can support you. Too often, patients skip this step—only to discover later that their plan won’t allow them to use their preferred pharmacy, or that starting treatment will be delayed while a new pharmacy is arranged.

What To Ask When Comparing Plans

To get the full picture, ask the plan to help you estimate your total yearly cost, including:

  • Monthly premium — what you pay each month
  • Annual deductible — what you must pay before coverage begins
  • Copays or coinsurance — for your specific medication
  • Annual out-of-pocket limits — compare medical and drug benefits separately. For covered Medicare Part D drugs, the 2027 annual out-of-pocket threshold is $2,400; it does not include plan premiums or Part B medical costs.

These numbers vary significantly between plans—and even small differences can add up quickly when you’re managing high-cost medications.

What We See Go Wrong

  • Patients thinking they must use their plan’s preferred specialty pharmacy: This is one of the most common misconceptions. When patients enroll in a new plan, they often receive letters stating they must use the plan’s preferred specialty pharmacy. Many assume this is mandatory and may even request to cancel their service with the existing specialty pharmacy — believing their plan “requires” it. In reality, this is rarely the case. Patients usually have the right to choose their specialty pharmacy and should feel empowered to speak up about who they want to provide their care.
  • High coinsurance for medical-benefit therapies: Part B and Medicare Advantage medical cost sharing can be substantial and is not subject to the Part D $2,400 cap. An example are 50/50 coinsurance with no max: You pay half the drug cost indefinitely, with no cap on your spending.
  • High deductibles: You may owe costs before coverage begins. The 2027 defined standard Medicare Part D deductible is $700, although individual plans may have different deductibles.
  • Mandated or excluded pharmacies: You could be forced to switch pharmacies or lose access entirely.
  • Delays from insurance approvals or site-of-care rules: Added steps can delay or block time-sensitive treatments.

When a Higher Premium Makes Sense

Sometimes, paying more per month gives you:

  • Better cost-sharing (like 80/20 instead of 50/50)
  • Lower coinsurance for infusions or injectables
  • Access to your preferred specialty pharmacy
  • Faster approvals with fewer administrative hurdles

Key Takeaway

Don’t shop by premium alone. Look at your total annual costs for your therapy and choose a plan that supports your therapy during Medicare open enrollment, minimizes delays, and keeps your out-of-pocket costs predictable.

3. Understand Plan Types

Some plans may restrict where you can get your treatment or how it’s billed:

Plan TypeWhat to Know
HMOTypically requires network providers and referrals or authorizations for some services; emergency exceptions apply.
EPOOften has limited out-of-network coverage other than emergencies; confirm specific plan terms.
PPOMore flexible. May allow out-of-network care and pharmacy exceptions.
Medicare Advantage (Part C)One card for A, B & in most cases D, but may limit access to preferred pharmacies or sites of care.
Original Medicare + Medigap + Part DOften best for specialty therapies. Medigap covers the 20% coinsurance under Part B but does not cover any out-of-pocket expenses under Part D.

4. Confirm How Your Therapy Is Billed

Ask the plan whether your medication is billed under:

  • Pharmacy Benefit (e.g., Part D or commercial pharmacy):
    Covers most self-administered drugs or some specialty meds. OON options are sometimes available.
  • Medical Benefit (e.g., Part B or commercial medical):
    Applies to many infused therapies like IVIG, TPN, and oncology treatments. Coverage rules vary and may require strict network use or prior authorization.

Understanding how your therapy is billed can help avoid surprises with network status, authorizations, and costs.

Medicare: What’s New in 2027

Medicare Part D: Out-of-Pocket Cap

Medicare introduced the annual Part D out-of-pocket cap of $2,000 in 2025. It increased to $2,100 in 2026 and will be $2,400 in 2027.

For 2027, the Part D annual out-of-pocket threshold is $2,400 for covered Part D drugs. Once the threshold is reached under Part D’s applicable counting rules, there is no additional cost sharing for covered Part D drugs for the remainder of the calendar year. Premiums and drugs not covered under Part D are not included in this cap.

This limit applies only to Part D medications (not Part B infusions) and helps patients on high-cost therapies predict their maximum drug costs.

💡 Why this matters: The Part D cap helps limit eligible prescription drug spending, but it does not limit the cost of Part B infusions or other medical services.

What to Know About the Monthly Payment Plan (Smoothing)

The Medicare Prescription Payment Plan, introduced in 2025, is a voluntary option offered by Medicare drug plans. It spreads eligible out-of-pocket Part D prescription costs into monthly bills from your plan instead of paying those amounts at the pharmacy.

For 2027, the Part D out-of-pocket threshold is $2,400. The payment plan does not reduce drug costs or change the annual cap; it only changes when you pay. Your monthly bill can vary depending on prescription spending and the number of months remaining in the year.

Enrolling does not mean you automatically owe the full $2,400. You owe only your actual eligible Part D cost-sharing amounts, up to the applicable annual limit.

Before enrolling in the Medicare Prescription Payment Plan (MPPP) for 2027, ask your provider whether there are any other copayment assistance options available.  AmeriPharma has a team dedicated to finding financial assistance solutions for your care.

If you receive Extra Help or other financial assistance, ask your plan and assistance program how payments and eligibility interact. Medicare beneficiaries generally cannot use manufacturer copay coupons for federally covered prescriptions; independent charitable assistance may have different rules.

Before enrolling, it’s a good idea to speak with an AmeriPharma Financial Assistance specialist who can walk you through how smoothing might affect your total cost. Depending on your situation, it may not be the best option.  Smoothing might sound helpful, but depending on your diagnosis, income, and medication, it could limit your access to assistance programs—and end up costing more.

Speak With a Specialist Today

(877) 778-0318 ext. 3341

Navigating Medicaid

We’re here to help you avoid treatment delays, explore financial assistance, and make confident insurance choices for 2027.

Medicaid rules vary by state. In most states, Medicaid does not cover out-of-network pharmacies—even for specialty drugs. However:

  • Medi-Cal (California Medicaid) may cover medications under the pharmacy benefit, which allows more flexibility.
  • Other states: Coverage is often limited or not accepted by our pharmacy. Contact us to check eligibility.

Medicare Tips for Specialty Patients

  • Original Medicare + Medigap + Part D
     Often the smoothest experience for specialty care. Medigap helps cover what Parts A & B don’t, and Part D handles outpatient prescriptions.
  • Medicare Advantage (Part C)
     These plans bundle A, B & D under a private insurer. They may require stricter prior authorization, mandate specific pharmacies, or limit your site of care.
  • Medi-Medi (Medicare + Medicaid)
     This setup can work well if Medicaid is truly secondary, but coverage rules and allowed amounts vary by state.

Navigating Employer & Marketplace Plans

If you’re reviewing a plan from your employer or the ACA Marketplace:

  • Start with the formulary: Is your drug covered? What tier? Any PA or quantity limits?
  • Ask about pharmacy mandates: Some plans require you to use a specific specialty pharmacy.
  • Watch out for:
    • 50/50 coinsurance with no cap
    • High deductibles (makes first fills expensive)

💡 Tip: Even if a plan is out-of-network, we may still be able to help—especially if your medication is under the pharmacy benefit. About 98% of patients in this situation are still covered when processed through pharmacy billing.

Financial Assistance: How We Can Help

  • External help first: We explore manufacturer copay programs and disease-specific foundations.
  • Internal help next: If external help isn’t available, we’ll check our internal support options.
  • What matters most:
    • Household income
    • Diagnosis
    • Medication prescribed
    • Insurance benefit type (Part B vs Part D)

Please avoid enrolling in Medicare Part D payment plans (smoothing) before talking to us—it can block access to some assistance programs.

Quick Checklist Before You Choose a Plan

Confirm your medication, strength, and site of care

Ask: Is it covered? What tier? Any limits or prior authorization?

Ask: Do I have to use a specific pharmacy?

Confirm if it’s billed under pharmacy or medical benefit

Estimate total cost: premium + deductible + coinsurance

Know your annual cap ($2,400 for Part D)

Start prior authorization early to avoid treatment gaps

Ask about manufacturer or foundation assistance

Call us before signing up for Part D payment plans

    Speak with an Insurance Coverage Specialist

    We’re here to help you review your coverage, check your benefits, and find out what assistance may be available. We’ll also help you prepare for insurance approvals so you don’t miss a dose when January 1 rolls around — especially if you’re making changes during Medicare Open Enrollment.

    Call Now To Speak With a Specialist

    (877) 778-0318 ext. 3341

    Alphanate SD: Everything You Need to Know About This Bleeding Disorder Treatment

    Published on by Dr. Saba Rassouli, PharmD

    Alphanate SD is a prescription medicine used to prevent and control bleeding episodes in people with hemophilia A. In the U.S., about 16 in 100,000 people have hemophilia A [5]. It is an inherited bleeding disorder where your blood does not clot properly because your body lacks a protein called factor VIII (FVIII). As a result, people with hemophilia A experience prolonged or excessive bleeding even from small injuries and surgeries.

    Do You Qualify for $0 Copay?

    Find Out Now
    (877) 778-0318

    Doctors can also use Alphanate during surgical or invasive procedures in adults and children with von Willebrand disease (VWD) when desmopressin (DDAVP) is ineffective or cannot be used. 

    If you or someone you love has hemophilia A or von Willebrand disease (VWD), Alphanate may be used in certain situations to help control or prevent excessive bleeding.  In this article, we will discuss everything you need to know about Alphanate SD, including its uses, dosage, side effects, and much more.

    What Is Alphanate SD?

    Alphanate is an FDA-approved human antihemophilic factor/von Willebrand factor complex used to control and prevent bleeding episodes in people with hemophilia A. It is also used during surgical or invasive procedures in certain adults and children with von Willebrand disease. 

    The FDA initially approved Alphanate in 1978 [1]. It is made from the plasma of thousands of blood donors. Alphanate contains two important blood-clotting proteins:

    • Factor VIII (FVIII): An essential protein needed for blood clotting.
    • Von Willebrand Factor (VWF): This is a protein that helps platelets attach to damaged blood vessels and also carries and stabilizes factor VIII in the bloodstream.

    The “SD” in “Alphanate SD” means solvent-detergent treatment. It is a manufacturing step used to reduce the risk of disease transmission in plasma-derived products.

    Alphanate is available as a sterile, lyophilized powder that is mixed with sterile water before intravenous (IV) injection. It is available in several strengths, including 250, 500, 1,000, and 2,000 IU of factor VIII per vial.

    What Is Alphanate Used For?

    Alphanate is FDA-approved for the following purposes [2][3]:

    Treatment and Prevention of Bleeding in Hemophilia A: People with hemophilia A have a lack of a protein called factor VIII, which is necessary for blood clotting. Alphanate temporarily replaces factor VIII and helps people with hemophilia A form stable blood clots.

    Surgical and Invasive Procedures in Hemophilia A: Alphanate can also be used to prevent and control bleeding before, during, and after surgery.

    Surgical and Invasive Procedures in von Willebrand Disease: Alphanate can be used in adults and children with type 1 and type 2 von Willebrand disease (VWD) during surgery when desmopressin (DDAVP) is ineffective or cannot be used. However, Alphanate is not indicated for people with severe type 3 VWD undergoing major surgery. 

    Please note that Alphanate does not cure hemophilia A or von Willebrand disease. Instead, it temporarily replaces deficient clotting factors to help control or prevent bleeding.

    Speak to a Specialist

    About Copay Assistance
    Learn More

    How Does Alphanate SD Work?

    To understand how Alphanate works, you first need to understand the role of factor VIII. When you bleed, your body activates a series of proteins known as clotting factors. Factor VIII participates in this process by working with activated factor IX to help activate factor X. This eventually leads to the formation of thrombin and fibrin, which strengthen the blood clot.

    People with hemophilia A have insufficient or defective factor VIII. As a result, their blood takes much longer to form a clot. Alphanate contains human factor VIII, which temporarily increases the amount of factor VIII in the bloodstream. This helps your body form a stronger blood clot.

    Alphanate also contains von Willebrand factor (VWF). VWF helps platelets attach to damaged blood vessels and also helps protect factor VIII from being broken down too quickly in the bloodstream.

    By replacing these important proteins, Alphanate controls bleeding in people with hemophilia A and supports blood clotting during surgery in people with von Willebrand disease.

    Alphanate SD Side Effects

    Like any other medicine, Alphanate can also cause some side effects. Some of them are mild, while others can be serious enough to require immediate medical attention. Here are some common and serious side effects of Alphanate [2][3]:

    Common Side Effects

    Here are some common side effects of Alphanate SD:

    Man experiencing back pain, a side effect of taking Alphanate sd
    • Respiratory distress
    • Back pain
    • Headache
    • Facial swelling
    • Pain
    • Fever
    • Chills
    • Itching and rash
    • Fatigue

    Contact your doctor if you experience side effects that persist, worsen, or concern you. 

    Severe Side Effects

    Serious side effects from Alphanate are rare, but they can occur. Here are some severe side effects of Alphanate:

    Severe Allergic Reaction: Alphanate can cause serious allergic reactions, including anaphylaxis. Get emergency help if you experience symptoms like hives, swelling, chest tightness, difficulty breathing, dizziness, or a sudden drop in blood pressure.

    Blood Clots: Blood clots (thrombosis) may occur with Alphanate, particularly in people with risk factors for thrombosis. Contact your doctor right away if you develop chest pain, trouble breathing, fainting, or pain and swelling in an arm or leg.

    Intravascular Hemolysis: Very large doses of Alphanate can cause destruction of red blood cells inside your blood vessels. This can lead to anemia. If this happens, your doctor may discontinue Alphanate treatment.

    Infections: Alphanate has a potential risk of transmitting infectious diseases because it is made from human plasma. Manufacturers take steps during production to reduce this risk, but they can’t eliminate it completely.

    Development of Inhibitors: Some people who receive Alphanate can develop antibodies called inhibitors. These antibodies can reduce the effectiveness of factor VIII and make bleeding more difficult to control.

    Please note that this is not a complete list of all possible side effects. Contact your doctor immediately if you experience any severe side effects of Alphanate SD.

    Get Financial Assistance

    (877) 778-0318

    Dosing of Alphanate SD

    Alphanate comes as a powder that’s mixed with sterile water before use and given by IV injection. The exact dose depends on several factors, such as body weight, the severity and location of the bleeding, factor VIII levels, the type of surgery, and how the person responds to treatment. Here are the usual recommended doses [3]:

    Hemophilia A: Your doctor will calculate your dose from your body weight and the factor VIII rise you need. Each IU of factor VIII per kg of body weight raises your factor VIII level by about 2% of normal. Minor bleeding may require lower doses, while major bleeding or surgery may require higher doses and a longer duration of treatment.

    Your doctor will check your factor VIII levels and adjust the dose and frequency based on how you respond.

    Von Willebrand Disease: For adults, the usual pre-operative dose is 60 IU VWF: RCo/kg, with 40 to 60 IU/kg every 8 to 12 hours afterward. For children, the dose is 75 IU/kg before the surgery, then 50 to 75 IU/kg every 8 to 12 hours. For a major surgery, you may need this for a week or more.

    Please note that the dosage described here is the usual recommended dosage. Your doctor will set the exact dose and length of treatment for you. 

    Before Starting Alphanate SD

    Before you start Alphanate, tell your doctor your complete medical history, including if you:

    • Previously had an allergic or severe hypersensitivity reaction to Alphanate or any of its ingredients
    • Have developed factor VIII inhibitors in the past
    • Have Type 3 von Willebrand disease
    • Have a history of blood clots or conditions that increase your risk of thrombosis
    • Are pregnant, planning to become pregnant, or breastfeeding
    • Have previously received factor VIII or VWF-containing products
    • Take any prescription medicines, vitamins, or herbal supplements

    Your doctor may monitor your factor VIII and VWF levels during treatment. Blood tests may also check whether you’ve developed inhibitors, especially if bleeding doesn’t respond to treatment as expected.

    Get Copay Assistance Now

    Schedule a Consultation

    Alphanate Cost

    The cost of Alphanate can vary considerably. The actual cost of Alphanate treatment depends on several factors, including your dosage, treatment schedule, insurance, and the pharmacy you visit.

    The wholesale acquisition cost (WAC) of Alphanate was about $1.38 per IU as of December 2025 [4].  Based on this price, a 70-kg person receiving a dose of 40–50 IU/kg would require approximately 2,800–3,500 IU. At $1.38 per IU, this would cost about $3,864–$4,830 before administration costs and other healthcare expenses. 

    Please note that these are rough estimates based on wholesale acquisition cost. The actual amount you pay may be different depending on your insurance, pharmacy, and other healthcare costs. Contact us if you are interested in financial assistance or copay assistance for Alphanate SD.

    BeneFIX: Uses, Dosage, Side Effects, and Safety

    Published on by Dr. Christine Leduc, PharmD

    BeneFIX injection is used to control active bleeding episodes, manage bleeding around surgery, and reduce the frequency of bleeding episodes in people with hemophilia B. 

    Do You Qualify for $0 Copay?

    Find Out Now
    (877) 778-0318

    BeneFIX Introduction and Uses

    BeneFIX is a brand-name prescription product. It contains the active ingredient recombinant coagulation factor IX. 

    This medication belongs to the drug class known as coagulation factors or hemostatics.

    A healthcare provider may prescribe this medication for children and adults with hemophilia B to:

    • Treat and control bleeding episodes 
    • Manage bleeding around surgery 
    • Reduce the frequency of bleeding episodes

    In people with hemophilia B, blood doesn’t clot properly, as they have a coagulation factor IX deficiency. Factor IX deficiency causes abnormal bleeding after injuries or surgery. Severe hemophilia B may cause spontaneous joint or muscle bleeds. 

    BeneFIX is not indicated for immune tolerance induction in people with hemophilia B. 

    BeneFIX comes as a white powder in single-use vials. The powder must be mixed with the provided liquid (diluent) before infusion into a vein. 

    Each BeneFIX kit contains:

    • Single-use vial
    • Sterile pre-filled diluent syringe
    • Vial adapter reconstitution device
    • Sterile infusion set
    • Two alcohol swabs
    • Bandage
    • Gauze pad

    The following strengths are available in the U.S.:

    • 250 IU
    • 500 IU
    • 1,000 IU
    • 2,000 IU
    • 3,000 IU

    BeneFIX Mechanism of Action

    BeneFIX temporarily replaces the missing clotting factor IX. This helps restore the clotting process and control bleeding. 

    Before Taking BeneFIX

    Before you receive your first dose of BeneFIX for hemophilia B, inform your healthcare provider if you:

    • Are allergic to any factor IX product or hamster proteins
    • Have or have had any medical conditions
    • Have or have previously developed factor IX inhibitors
    • Are breastfeeding
    • Are pregnant or planning to get pregnant

    Don’t use BeneFIX if you are allergic to factor IX, any ingredients of this product, or hamster proteins. 

    Get Financial Assistance

    Schedule a Consultation

    BeneFIX Dosing

    Before administering BeneFIX, your healthcare provider will use a specific formula to determine the initial dose. The dose and duration of the treatment depend on:

    • Age
    • Body weight
    • Severity of factor IX deficiency
    • Desired factor IX level
    • Patient’s condition
    • Location and extent of bleeding

    Dosing of BeneFIX to Control Bleeding Episodes and Manage Bleeding Around Surgery

    Minor bleeding: The dose is calculated to achieve a factor IX activity of 20% to 30% of normal. May be repeated every 12 to 24 hours. Treatment lasts 1 to 2 days. 

    Moderate bleeding: The dose is calculated to achieve a factor IX activity of 25% to 50% of normal. May be repeated every 12 to 24 hours. Treatment lasts until bleeding stops or healing occurs. This is typically 2 to 7 days. 

    Major bleeding: The dose is calculated to achieve a factor IX activity of 50% to 100% of normal. May be repeated every 12 to 24 hours. Treatment lasts 7 to 10 days. 

    Dosing for Routine Prevention of Bleeding Episodes

    For long-term protection against bleeding, the recommended dose is 100 IU/kg once weekly. Your healthcare provider may adjust the dose or frequency based on your clinical response. 

    Proper Use

    • Use this or any medication exactly as directed. 
    • Your healthcare provider may administer BeneFIX or teach you how to prepare and self-administer the medication. 
    • Ask your doctor or pharmacist if you have problems understanding any part of the Instructions for Use. 
    • The reconstituted solution should be clear and colorless. If it is not, don’t use it. 
    • Use the reconstituted solution immediately or within 3 hours of mixing. 
    • If you miss a scheduled dose, contact your healthcare provider for instructions. 
    • Call your healthcare provider immediately if you take more than the prescribed dose. 
    • Call your healthcare provider immediately if your bleeding does not stop after taking this medication. This may be a sign that the medication is not working as intended.

    BeneFIX Storage and Handling

    • Store BeneFIX at room temperature or in a refrigerator, between 2 and 30°C (36 and 86°F).
    • Don’t freeze.
    • Don’t use BeneFIX after the expiration date stated on the label.

    Speak to a Specialist

    About Copay Assistance
    (877) 778-0318

    BeneFIX Side Effects

    Common Side Effects

    Man on couch coughing and experiencing side effects of Benefix
    • Fever
    • Cough
    • Nausea
    • Pain, swelling, or redness at the injection site
    • Headache
    • Dizziness 
    • Rash

    Allergic Reactions

    Seek emergency medical care if you have:

    • Wheezing
    • Difficulty breathing
    • Chest tightness
    • Bluish lips and gums
    • Fast heartbeat
    • Swelling of the face
    • Rash
    • Hives

    Inhibitor (Antibody) Production

    Your healthcare provider will likely order tests to measure factor IX inhibitors in your blood if:

    • Factor IX level does not increase as expected after starting treatment
    • Bleeding does not stop with an appropriate dose

    Complications Due to Blocked Blood Vessels

    Factor IX products may increase the risk of a blood vessel being blocked by a circulating blood clot. The risk may be higher if you receive continuous infusions through a large vein. 

    Contact your healthcare provider immediately if you have:

    • Chest pain
    • Difficulty breathing
    • Leg tenderness
    • Swelling

    Get Copay Assistance Now

    Learn More

    BeneFIX Cost and Financial Assistance 

    The amount you pay for BeneFIX can vary depending on your prescribed dose, treatment frequency, insurance coverage, pharmacy, and location. Because BeneFIX dosing is individualized, treatment costs can vary between patients.

    Contact your insurance provider to find out if your plan covers BeneFIX or requires prior authorization. Insurance coverage and patient assistance programs may help reduce your out-of-pocket costs. Contact us if you are interested in exploring financial assistance or copay assistance for BeneFIX.

    Esperoct: Uses, Side Effects, Dosage, and More

    Published on by Dr. Samantha Kaeberlein, PharmD

    Esperoct is an FDA-approved injectable medicine used to treat and control bleeding episodes in people with hemophilia A. It is also used to manage bleeding around surgery and to reduce the frequency of bleeding episodes in people with hemophilia A.  

    Do You Qualify for $0 Copay?

    Find Out Now
    (877) 778-0318

    Introduction and Uses

    Esperoct is a brand-name prescription product. The active ingredient in this product is turoctocog alfa pegol. It is a lab-created form of factor VIII, also known as recombinant antihemophilic factor. 

    Because the active ingredient is conjugated with a polyethylene glycol molecule, Esperoct stays in the body longer than standard half-life factor VIII products. This extends factor VIII activity in the body. 

    Esperoct belongs to the drug class called coagulation factors or hemostatics. 

    A healthcare provider may prescribe Esperoct for adults and children with hemophilia A to:

    • Treat and control bleeding episodes 
    • Manage bleeding around surgery 
    • Provide routine prophylaxis to reduce the frequency of bleeding episodes 

    This medication should not be used to treat von Willebrand disease (VWD). 

    Mechanism of Action

    People with hemophilia A have deficient or dysfunctional clotting factor VIII. Factor VIII is necessary for the blood-clotting process. Its deficiency can cause prolonged or spontaneous bleeding into the joints, muscles, or internal organs.

    Esperoct works by temporarily replacing the missing clotting factor VIII in the blood, helping the blood form clots and control bleeding.

    Esperoct Dosing

    Your healthcare provider will calculate your dose based on your body weight, desired increase in factor VIII activity, clinical response, and treatment needs. Always use the dose prescribed specifically for you.

    Esperoct comes as a white to off-white powder in single-dose vials. It is available in nominal dosage strengths of approximately 500, 1,000, 1500, 2,000, 3,000, 4,000, and 5,000 International Units (IU) per vial. The powder must be mixed with the provided sterile sodium chloride solution and is administered through intravenous infusion.  

    Dosing of Esperoct To Control Bleeding Episodes

    Minor bleeding: 40 IU/kg for patients 12 years or older and 65 IU/kg for patients younger than 12 years. A single dose is typically sufficient. 

    Moderate bleeding: 40 IU/kg for patients 12 years or older and 65 IU/kg for patients younger than 12 years. An additional dose may be given after 24 hours. 

    Major bleeding: 50 IU/kg for patients 12 years or older and 65 IU/kg for patients younger than 12 years. Additional doses may be given approximately every 24 hours. 

    Dosing for Surgery 

    Minor surgery: 50 IU/kg for patients 12 years or older and 65 IU/kg for patients younger than 12 years before surgery. If required, additional doses may be given after 24 hours. 

    Major surgery: 50 IU/kg for patients 12 years or older and 65 IU/kg for patients younger than 12 years before surgery. Additional doses may be given approximately every 24 hours for the first 7 days and then approximately every 48 hours until wound healing. 

    Dosing for routine prophylaxis

    Patients 12 years or older: The starting dose is 50 IU/kg every 4 days. Dosing frequency may be adjusted based on bleeding episodes.

    Patients younger than 12 years: 65 IU/kg twice weekly. Dosing frequency may be adjusted based on bleeding episodes.

    Get Financial Assistance

    Contact Us

    Side Effects

    Common Side Effects

    Man on couch scratching an itch on his arm. Itching is one of the side effects of Esperoct.
    • Rash or itching
    • Swelling, pain, or redness at the injection site

    Serious side effects include allergic reactions and the development of neutralizing antibodies (inhibitors) against factor VIII. Seek emergency medical care if you develop symptoms of a severe allergic reaction such as itching, hives, tightness of the chest, wheezing, or facial swelling. Call your healthcare provider immediately if your bleeding does not stop after taking Esperoct. This may be a sign that the medication is not working as intended. 

    Important Information and Warnings

    Never attempt to inject this medication on your own unless you know how to safely administer it. Carefully follow your healthcare provider’s instructions about the dose and schedule for administering Esperoct. 

    Severe Allergic Reactions

    Seek emergency medical care if you experience any signs of an allergic reaction, such as:

    • Hives
    • Chest tightness
    • Wheezing
    • Dizziness
    • Difficulty breathing
    • Swelling of the face

    Inhibitor (Antibody) Production

    In some cases, your body can develop proteins called inhibitors (antibodies) against factor VIII, which can prevent this medication from working properly. Your healthcare provider will likely order tests to measure factor VIII inhibitors in your blood if:

    • Factor VIII level doesn’t increase as expected after starting treatment
    • Bleeding doesn’t stop with an appropriate dose

    Before Taking Esperoct

    Before using Esperoct, tell your healthcare provider if you:

    • Have any known allergies 
    • Have or have had any medical conditions
    • Have or have previously developed factor VIII inhibitors
    • Are breastfeeding
    • Are pregnant or planning to get pregnant

    Don’t use Esperoct if you are allergic to factor VIII, any ingredients of Esperoct, or hamster proteins. 

    Get Copay Assistance Now

    (877) 778-0318

    Proper Use

    Use this or any medication exactly as directed. You may receive your first dose in a hospital, clinic, or treatment center. If home treatment is appropriate, your healthcare provider will teach you how to prepare and administer the medication safely. Ensure you are comfortable with the instructions prior to preparing the medication yourself.

    • Read and follow the Instructions for Use included with the product
    • Wash your hands and work on a clean surface
    • Only take out the exact number of packages you need
    • Bring the kit to room temperature
    • Administer Esperoct at room temperature and follow your healthcare provider’s instructions for the infusion rate. Do not infuse faster than instructed. 
    • Use only the supplies provided or specifically recommended by your healthcare provider
    • Your healthcare provider may order blood tests to monitor factor VIII activity and your response to treatment. 
    • Check the reconstituted solution before infusion. It should be clear and colorless, with no visible particles.
    • Use the reconstituted solution immediately. If you cannot, use it within 4 hours when stored at or below 86ºF (30°C) or within 24 hours when stored in a refrigerator at 36°F to 46°F (2°C to 8°C).
    • If you miss a dose, infuse the missed dose as soon as you remember. Never use a double dose to make up for a missed dose. 
    • Call your healthcare provider immediately if you infuse more than the prescribed dose. 

    Storage and Handling

    • Store the unmixed vials in the original container protected from light. 
    • Don’t freeze. 
    • You may store it in a refrigerator at 36°F to 46°F (2°C to 8°C) for up to 30 months until expiration. 
    • Until expiration, you may store it at room temperature (don’t exceed 86°F or 30°C) for up to 12 months, or up to 3 months at temperatures not exceeding 104°F (40°C).
    • If you choose to store this medication at room temperature, never put it back in the refrigerator. 

    Speak to a Specialist

    About Copay Assistance
    Get Started

    Esperco Cost and Financial Assistance 

    Cost can vary depending on your prescribed dose, treatment frequency, insurance coverage, location, and pharmacy. Contact your insurance provider to find out if your plan covers Esperoct or requires prior authorization.

    Manufacturer assistance programs or other financial assistance may be available to eligible patients and could help reduce out-of-pocket costs. Contact us if you are interested in exploring financial assistance or copay assistance for Esperoct.

    Koāte: Uses, Dosage, Side Effects, Warnings, and Cost

    Published on by Dr. Mark Alfonso, PharmD, BCMTMS

    Koāte-DVI (also marketed as KOĀTE) is an FDA-approved injectable drug used for the control and prevention of bleeding in people with hemophilia A. It works by temporarily replacing the clotting factor VIII protein and helps the blood clot properly.  

    Get Copay Assistance Now

    (877) 778-0318

    Koāte-DVI is also known by its generic name, antihemophilic factor (human), meaning it is derived from donated human plasma. Koāte-DVI belongs to the coagulation factors and hemostatic drug class and is only available with a doctor’s prescription. 

    This article discusses everything you need to know about Koāte-DVI, including its uses, benefits, recommended dose, possible side effects, and important safety information. 

    Indication

    Koāte-DVI (antihemophilic factor [human]) is used to control and prevent bleeding episodes in people with hemophilia A. It is also used to manage bleeding during emergency or elective surgery in people with hemophilia A. 

    This drug is not indicated for the treatment of von Willebrand disease. 

    Mechanism of Action

    In patients with hemophilia A, the clotting factor VIII is either missing or not functioning properly. As a result, people with hemophilia A may bleed longer and more frequently than people with a normal amount of clotting factor VIII in their body. 

    Koāte-DVI, a human plasma-derived Factor VIII, temporarily replaces the missing or nonfunctional clotting factor VIII when infused and helps control bleeds in people with hemophilia A. The half-life of Koāte-DVI can vary between patients. 

    Koāte-DVI: Drug Form

    Koāte-DVI is available as a lyophilized powder for reconstitution in single-use vials containing 250 IU (yellow), 500 IU (blue), and 1,000 IU (red) of Factor VIII activity. 

    Every vial of Koāte-DVI comes with a Mix2Vial transfer device, allowing for needle-free reconstitution. You can ask your healthcare provider about the Mix2Vial Practice Kit for step-by-step Koāte-DVI administration instructions to help you become comfortable with the reconstitution process. 

    Koāte-DVI: Dosage 

    The dosage and frequency of Koāte-DVI are adjusted according to the patient’s clinical condition, the severity of the Factor VIII deficiency, and the location and extent of bleeding. 

    Koāte-DVI Dosage by Type of Bleeding Episodes

    The recommended dosage of Koāte-DVI based on the type of bleeding is as follows:

    Minor bleeding

    If you experience a minor bleed such as large bruises, significant cuts or scrapes, or uncomplicated joint hemorrhage, a dose of 15 IU/kg may be given every 12 hours until bleeding stops and healing occurs (usually 1–2 days). 

    Moderate bleeding

    If you experience moderate bleeding (e.g., from the nose, mouth, or gums), dental extractions, or hematuria, a dose of 25 IU/kg may be given every 12 hours until healing occurs (an average of 2–7 days). 

    Major bleeding

    If you experience major bleeding such as joint or muscle hemorrhage, major trauma, hematuria, or intracranial or intraperitoneal bleeding, an initial dose of 40–50 IU/kg may be given, followed by a maintenance dose of 25 IU/kg every 12 hours. Treatment may continue until healing is achieved, for up to 10 days. Intracranial bleeding may require prophylactic therapy for up to 6 months. 

    Speak to a Specialist

    About Copay Assistance
    Get Started

    Koāte-DVI Dosage for Surgery 

    The recommended dosage of Koāte-DVI for surgery is as follows: 

    • Before surgery, you may receive a dose of 40–50 IU/kg once to achieve an FVIII level of 80–100%.
    • After surgery, a dose of 30–50 IU/kg every 12 hours is recommended to maintain FVIII levels of 60–100% for 7–10 days or until healing is achieved.

    How Koāte-DVI Is Given

    Koāte-DVI is given intravenously (IV) after the powder is mixed with sterile water. Follow your healthcare provider’s instructions for preparing and administering Koāte-DVI. 

    The prepared solution should be used within 3 hours and should not be refrigerated after mixing. The IV administration rate should not exceed 10 ml per minute. Your healthcare provider will adjust the administration rate according to your tolerance and condition. 

    Side Effects

    The most common side effects associated with Koāte-DVI infusion include:

    Man clutching stomach, experiencing abdominal pain after using Koāte-DVI
    • Nervousness
    • Headache
    • Abdominal pain (stomach ache)
    • Nausea
    • Tingling sensation, “pins and needles” in your face, arms, or ears
    • Blurred vision

    Severe Side Effects

    While less common, it is possible that you may experience severe allergic reactions to Koāte-DVI. The common signs and symptoms of allergic reactions are as follows:

    • Hives
    • Chest tightness
    • Wheezing
    • Difficulty breathing
    • Feeling light-headed
    • Fainting
    • Swelling of your face, lips, tongue, or throat
    • Stomach cramps
    • Joint pain
    • Low blood pressure

    Get immediate medical help if you experience symptoms of a severe allergic reaction. In that case, your healthcare provider will discontinue the Koāte-DVI treatment and administer the appropriate treatment. 

    Do You Qualify for $0 Copay?

    Find Out Now
    (877) 778-0318

    Warnings and Precautions

    There are some important warnings and precautions to be aware of before starting and during treatment with Koāte-DVI: 

    • Develop Factor VIII inhibitors: Your body may make antibodies that reduce or stop Koāte-DVI from working properly. Tell your healthcare provider if the medicine does not control your bleeding as well as expected.
    • Develop anemia from red blood cell breakdown: Large or frequent doses of Koāte-DVI may cause red blood cells to break down, especially if you have blood type A, B, or AB. Your healthcare provider may do blood tests to check for this problem.
    • Transmission of infectious agents: Because Koāte-DVI is made from human blood, it may carry a risk of transmitting infectious agents. Measures are used during manufacturing to reduce this risk, but the possibility of transmitting infectious diseases cannot be completely eliminated. 

    Information to Tell Your Healthcare Provider

    To make sure Koāte-DVI treatment is safe for you, it is important to share your medical history with your doctor. Tell your healthcare provider if you:

    • Are pregnant or plan to become pregnant (because there are not enough data to determine the drug-associated risk during pregnancy) 
    • Are breastfeeding (because it is not known whether Koāte-DVI passes into human milk or affects a breastfed baby or milk production) 
    • Have any planned surgeries or dental procedures
    • Are taking any over-the-counter medications or other coagulation factors, supplements, or herbal products
    • Have been told that you have inhibitors to factor VIII because Koāte-DVI may not work for you

    Koāte-DVI: Cost

    The cost of Koāte-DVI can vary depending on your Factor VIII requirements, body weight, treatment frequency, insurance coverage, and the number of vials needed. 

    Eligible patients with commercial insurance and financial need may qualify for the manufacturer’s copay assistance program, subject to program terms and eligibility requirements. Contact us if you are interested in exploring financial assistance or copay assistance for Koāte-DVI.

    The manufacturer also offers the KOĀTE TRY-IT Program, which allows eligible patients to try Koāte-DVI for up to 2 weeks at no cost, with a maximum of 50,000 IU. To qualify, patients must not currently be using Koāte-DVI and must not have a currently diagnosed Factor VIII inhibitor.

    Kovaltry (Recombinant Factor VIII): Uses, Dosage, Side Effects, and More

    Published on by Dr. Robert Hakim, PharmD

    Kovaltry (antihemophilic factor VIII, recombinant) is a prescription medication for the treatment of hemophilia A, also known as congenital factor VIII deficiency. Kovaltry is used to help control active bleeding episodes, prevent future bleeds, and manage surgery-associated bleeding in people with hemophilia A. 

    Get Copay Assistance Now

    (877) 778-0318

    Kovaltry is a recombinant coagulation factor VIII replacement therapy. The FDA approved it in 2016 after clinical studies showed its safety and effectiveness in people with hemophilia A. 

    Clinical trials found that Kovaltry provided effective bleeding prevention in people with hemophilia A when used as routine prophylaxis (prevention) two or three times per week. Common side effects such as fever, rash, and headache were also reported. 

    If your healthcare provider has prescribed you Kovaltry, read on to learn how this medication is used, the potential side effects it can cause, and the important safety information you must know before treatment. 

    Kovaltry: FDA-Approved Uses

    Kovaltry (antihemophilic factor VIII, recombinant) is only approved to treat adults and children with hemophilia A. It is typically prescribed for the following:

    • Prophylaxis to prevent or reduce the frequency of bleeding episodes
    • As an on-demand treatment to control bleeding episodes 
    • As perioperative management to control bleeding during and after surgery 

    Kovaltry is not indicated for the treatment of von Willebrand disease. Von Willebrand disease is an inherited bleeding disorder caused by deficient or dysfunctional von Willebrand factor, a protein that plays an important role in normal blood clotting. 

    Mode of Action

    People with hemophilia A have deficient or dysfunctional clotting factor VIII, a protein needed for normal blood clotting. Deficient factor VIII activity can result in bleeding into joints, muscles, or internal organs, either spontaneously or following accidental or surgical trauma. 

    Kovaltry is a recombinant drug made in the laboratory. The active substance in Kovaltry, Octocog alfa, is designed to mimic the function of natural clotting factor VIII. Once infused into the bloodstream, Kovaltry replaces deficient factor VIII and helps promote blood clotting. By temporarily increasing factor VIII activity, Kovaltry helps control or prevent bleeding in people with hemophilia A. 

    Drug Form

    Kovaltry is available as a single-use vial containing dry, white-to-slightly-yellow factor VIII powder. The medication comes in five FVIII dosage strengths, expressed in international units (IUs). They are labeled and color-coded:

    • Blue: 250 IU dosage strength
    • Green: 500 IU dosage strength
    • Red: 1,000 IU dosage strength
    • Yellow: 2,000 IU dosage strength
    • Gray: 3,000 IU dosage strength

    Each vial with the labeled strength of recombinant factor VIII is mixed with the provided diluent (sterile water) before infusion. 

    Speak to a Specialist

    About Copay Assistance
    Get Started

    Dosage and Administration

    Kovaltry is given as an intravenous infusion (injected directly into a vein) over several minutes. Your healthcare provider will infuse the first dose and determine the rate of administration that is best for you. 

    Your healthcare provider will determine your individual dose based on factors such as your weight, factor VIII levels, bleeding severity, clinical response, and treatment goals. 

    Dosage of Kovaltry for Routine Prophylaxis

    The recommended dose for adults and adolescents (≥ 12 years of age) is 20 to 40 IU/kg, given two or three times a week. For children younger than 12 years, the recommended dose is 25 to 50 IU/kg, given two or three times a week or every other day. 

    Dosage of Kovaltry for On-Demand Treatment of Bleeding

    The dosage of Kovaltry is adjusted according to the severity of bleeding. The following are the dosages for treating bleeding ranging from minor to major: 

    • Minor bleed: The target factor VIII level is 20–40 IU/dl. Kovaltry may be administered every 12–24 hours for at least 1 day, or until the bleeding is resolved. 
    • Moderate bleed: The target factor VIII level is 30–60 IU/dl. Kovaltry may be administered every 12–24 hours for 3–4 days or longer, depending on the clinical response. 
    • Major bleed: The target factor VIII level is 60–100 IU/dl. Kovaltry may be administered every 8–24 hours until the bleeding is resolved.

    Dosage of Kovaltry for Bleeding Associated with Surgery

    For surgery, the recommended factor VIII levels are:

    • Minor surgery: 30–60 IU/dl before and after surgery; repeat every 24 hours for at least 1 day or until healing is achieved. 
    • Major surgery: 80–100 IU/dl before and after surgery; repeat every 8–24 hours until adequate wound healing, followed by continued therapy to maintain factor VIII activity at 30–60 IU/dl for at least another 7 days.

    Possible Side Effects

    A boy scratching his arm because of an itch, which is a common side effect of using Kovaltry

    The most frequently reported side effects of Kovaltry include: 

    • Headache
    • Fever
    • Itching and rash
    • Injection-site reactions such as burning and stinging at the injection site
    • Chills
    • Flushing

    Some people receiving Kovaltry may develop neutralizing antibodies called factor VIII inhibitors. These antibodies can reduce or prevent Kovaltry from working effectively. Your healthcare provider may perform blood tests to check for inhibitors, particularly if bleeding is not adequately controlled. 

    Although less common, serious allergic reactions, including life-threatening anaphylaxis, can occur with Kovaltry. Symptoms of an allergic reaction may include:

    • Chest or throat tightness
    • Difficulty breathing or wheezing
    • Dizziness
    • Hives or rash
    • Nausea
    • Low blood pressure

    Stop using Kovaltry and seek immediate medical attention if you develop signs of a severe allergic reaction.

    Do You Qualify for $0 Copay?

    Find Out Now
    (877) 778-0318

    Precautionary Measures

    To ensure Kovaltry is safe for you, tell your healthcare provider if you:

    • Have any medical problems such as heart disease or are at risk for heart disease
    • Have any planned surgeries or procedures
    • Are pregnant or plan to become pregnant 
    • Are breastfeeding or plan to breastfeed
    • Have any allergies, including allergies to Kovaltry or hamster or mouse proteins 
    • Are taking any over-the-counter medications or other coagulation factors, supplements, or herbal products
    • Have been told that you have factor VIII inhibitors, as they may reduce the effectiveness of Kovaltry 

    Kovaltry: Cost

    The cost of Kovaltry can vary from person to person. Your dose, how often you receive treatment, insurance coverage, pharmacy, and location can all affect how much you pay. Since Kovaltry dosing is based on body weight and individual treatment needs, costs may differ considerably between patients.

    Insurance and financial assistance programs may help lower your out-of-pocket costs. Contact us for help finding financial assistance and copay assistance for Kovaltry.

    NovoSeven: A Complete Guide to Uses, Dosage, and Side Effects

    Published on by Dr. Saba Rassouli, PharmD

    NovoSeven is an injectable medicine used to treat and prevent bleeding episodes in people with hemophilia and other bleeding disorders. It is also known by its generic name, coagulation factor VIIa (recombinant), which means this drug is produced through recombinant technology in the laboratory.

    NovoSeven belongs to a class of medications called hemostatic agents, which promote blood clot formation at the site of bleeding when natural blood-clotting proteins are absent or not functioning properly. 

    Get Financial Assistance

    (877) 778-0318

    NovoSeven was first approved by the U.S. FDA in 1999. In 2008, a room-temperature-stable formulation, NovoSeven RT (coagulation factor VIIa [recombinant]), became available in the United States. 

    NovoSeven RT is only available with a doctor’s prescription. Read on to learn when NovoSeven RT is used, how it works, its possible side effects, and what precautionary measures you should take. 

    FDA-Approved Uses

    NovoSeven RT (coagulation factor VIIa [recombinant]) is approved to treat bleeding episodes and manage bleeding during or after surgical procedures in:

    • Adults and children with hemophilia A or B with inhibitors (antibodies) against clotting factor VIII or IX
    • Adults and children with congenital factor VII (FVII) deficiency
    • Adults and children with Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
    • Adults with acquired hemophilia

    BOXED WARNING

    NovoSeven RT can cause blood clots (thrombosis) in your arteries and veins, leading to symptoms such as chest pain, severe headache, shortness of breath, coughing up blood, swelling, redness or discoloration, or paralysis on one side of the body. Get immediate medical care if you experience any of these symptoms. 

    Mode of Action

    Whether you have hemophilia A or B, your healthcare provider will treat you by replacing the missing clotting factors (FVIII or IX). However, sometimes this treatment stops working when your body develops inhibitors (antibodies) against the clotting factor being replaced. 

    NovoSeven RT, which contains the active ingredient eptacog alfa (activated), acts as a bypassing agent. It helps promote blood clot formation at the site of injury without relying on factor VIII or IX, which may be blocked by inhibitors. 

    In short, NovoSeven RT helps control bleeding when the body’s clotting factors are reduced, absent, or not functioning properly. Additionally, NovoSeven RT can also be used in people with factor VII deficiency, where the body does not produce enough of this clotting factor.

    NovoSeven RT: Drug Form

    NovoSeven RT comes as a powder that is reconstituted with the provided diluent before administration. This drug is available in single-use vials of 1 mg, 2 mg, 5 mg, or 8 mg recombinant coagulation factor VIIa (FVIIa). 

    NovoSeven RT with MixPro kits are also available from a specialty pharmacy distributor for self-administration. This kit comes in a compact package that contains: 

    • Vial with NovoSeven RT powder
    • Vial adapter
    • Prefilled syringe with diluent
    • Plunger rod

    Connect With a Copay Assistance Specialist

    Get Started

    Dosage and Administration

    The dosage of NovoSeven RT depends on your body weight (kg), the type of bleeding disorder you have, and whether it is being used to treat bleeding or prevent bleeding during surgery. 

    1. Dosage for Hemophilia A or B with Inhibitors

    The recommended dosage for hemophilia A or B with inhibitors is 90 mcg/kg every 2 hours until hemostasis is achieved. For severe bleeding episodes, treatment may then continue at 90 mcg/kg every 3 to 6 hours after hemostasis is achieved, if continued treatment is needed.  

    If a patient is undergoing a surgical procedure, the NovoSeven RT dose may vary depending on the type of surgery. For instance: 

    • Minor surgery: 90 mcg/kg immediately before surgery, then every 2 hours during surgery. After surgery, 90 mcg/kg every 2 hours for 48 hours, followed by every 2 to 6 hours until healing occurs.
    • Major surgery: 90 mcg/kg immediately before surgery, then every 2 hours during surgery and for 5 days after surgery. The dose may then be given every 4 hours until healing occurs.

    2. Dosage for Congenital Factor VII Deficiency

    For adults and children with congenital factor VII deficiency, the recommended dosage of NovoSeven RT to treat bleeding episodes is 15 to 30 mcg/kg every 4 to 6 hours until the bleeding stops.

    In case of bleeding related to surgery, a dose of 15 to 30 mcg/kg is given before surgery and every 4 to 6 hours during surgery. 

    3. Dosage for Glanzmann’s Thrombasthenia

    The typical NovoSeven RT dosage for adults and children with Glanzmann’s thrombasthenia to treat bleeding episodes is 90 mcg/kg every 2 to 6 hours until the bleeding stops. 

    The typical NovoSeven dosage to prevent bleeding related to surgery is 90 mcg/kg right before surgery, followed by repeated doses every 2 hours during surgery, and then every 2 to 6 hours after surgery to maintain hemostasis.

    4. Dosage for Acquired Hemophilia

    For adults with acquired hemophilia, the recommended dosage of NovoSeven RT for bleeding episodes is 70 to 90 mcg/kg every 2 to 3 hours until hemostasis is achieved.

    For surgical procedures, the recommended dosage is 70 to 90 mcg/kg immediately before surgery and every 2 to 3 hours during surgery and until hemostasis is achieved.

    NovoSeven RT: How to Take

    NovoSeven RT is administered by intravenous (IV) bolus injection into a vein over 2 to 5 minutes. Initially, it is administered by the healthcare provider. If you will administer NovoSeven RT at home, your healthcare provider should train you on how to properly prepare and administer it. 

    NovoSeven RT must be reconstituted with the provided diluent before use. Follow the product instructions and your healthcare provider’s directions for preparing, storing, and using the reconstituted medication. 

    Possible Side Effects

    Woman experiencing nausea after taking NovoSeven

    The most serious adverse reaction associated with NovoSeven RT is abnormal blood clot formation (thrombosis). Serious blood clots can form in the veins or arteries and may lead to complications such as stroke, heart attack, or pulmonary embolism.

    Other adverse reactions reported with NovoSeven RT vary depending on the condition being treated and may include fever, nausea, vomiting, and injection-site reactions.

    Serious allergic reactions, including anaphylaxis, can also occur. Get immediate medical help if you experience chest pain, shortness of breath, a sudden severe headache, swelling or pain in an arm or leg, or signs of a severe allergic reaction.

    Do You Qualify for $0 Copay?

    Find Out Now
    (877) 778-0318

    NovoSeven RT: Warnings and Precautions 

    Before taking NovoSeven RT, tell your healthcare provider if you:

    • Have a history of heart or blood vessel disease
    • Are an older patient, particularly with acquired hemophilia, and receiving other agents to stop bleeding
    • Are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies
    • Have had an allergic reaction to any factor VIIa product before using NovoSeven RT
    • Have any allergies, including allergies to mouse, bovine, or hamster proteins
    • Have been told that you have inhibitors to factor VIIa (because NovoSeven RT may not work for you)
    • Are pregnant or planning to become pregnant
    • Are breastfeeding

    Estimated Cost

    NovoSeven RT is an expensive specialty medicine because currently there is no generic version available. Therefore, the actual cost of this drug may vary depending on the number of vials you need for the treatment, your insurance coverage, and the pharmacy you visit.

    Moreover, Novo Nordisk, the manufacturer of NovoSeven RT, offers financial support to patients through its NovoCare program, which includes a Copay Assistance Program and Patient Trial Program (qualified patients receive 6 doses of NovoSeven RT). Contact us if you are interested in financial or copay assistance for NovoSeven, as we can help you find and apply for the right program.